Condition: Transplant-Related Lung Cancer · Sponsor: Marc de Perrot
This is a prospective phase I study to determine the safety and feasibility of non-ablative oligofractionated radiation therapy (NORT) before lung transplantation for patients with underlying pulmonary malignancy. We hypothesize that heterogeneous dose distributions could generate a vaccination effect against the tumor by creating anti-tumoral immune response in the body and these patients may be immunized against their tumor which could reduce the risk of cancer recurrence after transplantation despite the anti-rejection medications required for the transplantation.
This description comes directly from the study's public registry record.
Marc de Perrot, MD, MSc · 416 340-5549 · marc.deperrot@uhn.ca
John Cho, MD, PhD · 416-946-4501 · John.Cho@rmp.uhn.ca
Always discuss trial participation with your own doctor first.
| Toronto General Hospital, University Health Network | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04782752